Jasper Therapeutics Holds Annual Stockholders Meeting

Jasper Therapeutics ( (JSPR) ) just unveiled an update.

On July 3, 2025, Jasper Therapeutics held its Annual Meeting of Stockholders, where approximately 80% of the voting common stock was represented. During the meeting, stockholders elected three Class I directors, ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor, approved executive compensation, and decided to hold annual advisory votes on executive compensation. These decisions reflect the company’s commitment to transparency and shareholder engagement, potentially strengthening its governance and stakeholder relations.

The most recent analyst rating on (JSPR) stock is a Buy with a $80.00 price target. To see the full list of analyst forecasts on Jasper Therapeutics stock, see the JSPR Stock Forecast page.

Spark’s Take on JSPR Stock

According to Spark, TipRanks’ AI Analyst, JSPR is a Underperform.

Jasper Therapeutics faces significant financial challenges with a lack of revenue and ongoing losses, leading to a low financial performance score. The technical analysis indicates bearish momentum, and the negative valuation metrics highlight the stock’s unattractiveness. Without earnings call data or notable corporate events, the overall outlook remains concerning.

To see Spark’s full report on JSPR stock, click here.

More about Jasper Therapeutics

Jasper Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for hematologic diseases. The company is committed to advancing its pipeline of transformative treatments to address unmet medical needs.

Average Trading Volume: 250,826

Technical Sentiment Signal: Sell

Current Market Cap: $86.23M

For detailed information about JSPR stock, go to TipRanks’ Stock Analysis page.